{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040500","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.996905+00:00","generated_at":"2026-06-08T04:50:34.409388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INVO Q3 revenue surges 314% to $974,894; clinics generate positive net income; merger with NAYA pending","bullets":["Revenue $974,894 (+314% YoY); pro forma revenue incl. full WFI quarter ~$1.5M (+534%).","Net loss $(1.2)M improved from $(2.5)M; pro forma net loss $(1.0)M.","Adjusted EBITDA $(0.6)M vs $(2.0)M; pro forma $(0.3)M; clinics profitable excluding corporate overhead.","Cash & equivalents $1.1M as of Sep 30, 2023.","Merger with NAYA Biosciences (all-stock) - closing conditions including shareholder approval and $5M+ PIPE not yet satisfied."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040500","json":"https://secwatch.observer/filing/0001493152-23-040500.json","markdown":"https://secwatch.observer/filing/0001493152-23-040500.md","text":"https://secwatch.observer/filing/0001493152-23-040500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223040500/0001493152-23-040500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223040500/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:50:34.409388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f16e1ccab2198e57d0868b603c3359bf0568642","claim":"INVO Fertility, Inc. reported financial results for the three months ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended September 30, 2023. The text of the press release is furnished as Exhibit 99.1 to this current report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223040500/0001493152-23-040500-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}